Liquidia Stock (NASDAQ:LQDA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$19.60

52W Range

$8.26 - $19.94

50D Avg

$15.18

200D Avg

$13.62

Market Cap

$1.69B

Avg Vol (3M)

$2.42M

Beta

-0.01

Div Yield

-

LQDA Company Profile


Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

170

IPO Date

Jul 26, 2018

Website

LQDA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 20
Research and Development Services-
Promotion Agreement$739.63K

Fiscal year ends in Dec 24 | Currency in USD

LQDA Financial Summary


Dec 24Dec 23Dec 22
Revenue$14.00M$17.49M$15.94M
Operating Income$-121.29M$-73.38M$-38.77M
Net Income-$-78.50M$-38.37M
EBITDA$-121.29M$-70.05M$-34.72M
Basic EPS$-1.66$-1.21$-0.63
Diluted EPS$-1.66$-1.21$-0.63

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 25May 10, 25 | 8:30 AM
Q4 24Mar 19, 25 | 8:30 AM
Q3 24Nov 13, 24 | 8:30 AM

Peer Comparison


TickerCompany
KZRKezar Life Sciences, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
KNSAKiniksa Pharmaceuticals, Ltd.
DAWNDay One Biopharmaceuticals, Inc.
VRCAVerrica Pharmaceuticals Inc.
LRMRLarimar Therapeutics, Inc.
SRRKScholar Rock Holding Corporation
MNKDMannKind Corporation
UTHRUnited Therapeutics Corporation